摘要
目的:分析前列腺癌患者血清miR-146a与miR-152的表达水平及临床意义。方法:以2009年1月至2013年4月在我院泌尿外科诊治的前列腺癌、良性前列腺增生患者及健康体检志愿者各46例为研究对象,分析各组患者血清miR-146a与miR-152的表达水平及与临床病理参数之间的关系。结果:miR-146a在前列腺癌患者血清中的表达水平显著高于良性前列腺增生及正常组血清,且前列腺良性增生组血清中miR-146a的表达量亦较正常组高,差异均具有统计学意义(P<0.05);miR-152在前列腺癌患者较良性前列腺增生及正常组血清显著偏低(P<0.05),但在良性前列腺增生和正常组之间无统计学差异(P>0.05);血清miR-146a在不同病理分期、临床分期、有无骨转移及血清t PSA有关(P<0.05),与年龄无关(P>0.05);而miR-152与不同病理分期、临床分期、有无骨转移有关(P<0.05),与血清t PSA水平无相关性(P>0.05),与年龄无显著相关性(P>0.05)。结论:miR-146a与miR-152在前列腺癌患者血清中的表达水平发生了显著改变,为用于前列腺癌的早期诊断及病程的判断提供了相关实验依据。
Objectives：To analyze serum circulating miR-146a and miR-152 expression levels of prostate cancer patients and their clinical significance.Methods：Prostate cancer,benign prostatic hyperplasia patients and healthy volunteers from July 2012 to April 2013 in our hospital were recruited for the study,46 cases in each group.The serum miR-146a,miR-152 expression levels and correlativity with clinic pathological parameters were analyzed.Results：The miR-146a expression levels in the serum of prostate cancer group was significantly higher than these in benign prostatic hyperplasia group and normal group,and miR-146a expression levels in the serum of benign prostatic hyperplasia group was higher than normal group,with statistically significant difference （P〈0.05）;miR-152 in prostate cancer group was decreased significantly compared with benign prostatic hyperplasia group and normal group （P〈0.05）,but no significant difference was found between benign prostatic hyperplasia and normal group （P〈0.05）;serum miR-146a was related with different pathological stage,clinical stage,with or without bone metastases （P〉0.05）.Serum miR-146a had no relationship with serum t PSA （p〉 0.05）;whereas miR-152 was related with various pathologic stage,clinical stage,with or without bone metastasis （P〈0.05）,but serum t PSA levels had no correlation with miR-152 （P〉0.05）.Conclusion：Serum miR-146a and miR-152 expression levels of prostate cancer patients have significant changes,which provides relevant experimental basis for the early diagnosis of prostate cancer and determine the course.
出处
《中国性科学》
2016年第4期7-10,共4页
Chinese Journal of Human Sexuality
基金
浙江省宁波市自然科学基金项目(2010A610051)
